Microbiome dysbiosis in long COVID: a scoping review of mechanistic insights, symptom associations, and therapeutic targets.

Publication date: Aug 29, 2026

The human microbiome, particularly the gut microbiome, plays a critical role in host immunity, metabolism, and barrier function. Emerging evidence suggests that persistent alterations in microbiome composition-termed dysbiosis-may contribute to the development and symptom persistence of Long COVID. To map the available literature on microbiome dysbiosis in relation to Long COVID, identify key microbial alterations, associated symptoms, and evaluate potential microbiome-targeted interventions. The scoping review followed Joanna Briggs Institute (JBI) methodological guidance and was reported according to PRISMA-ScR. A comprehensive search of PubMed, Scopus, Web of Science, and Cochrane Library databases was conducted for studies published from January 2000 to May 2025. Eligible studies included human subjects with a clinical diagnosis of Long COVID and microbiome-related outcomes. Data was charted using a standardized form and synthesized narratively and descriptively. A total of 62 sources were included, most of which were narrative, conceptual, or descriptive in nature. The available literature most frequently discussed gut microbiome dysbiosis in relation to Long COVID, including reduced abundance of beneficial taxa such as Faecalibacterium prausnitzii and Bifidobacterium adolescentis, and increased abundance of opportunistic or pro-inflammatory taxa such as Ruminococcus gnavus and Clostridium innocuum. Reported or proposed associations involved fatigue, gastrointestinal symptoms, neuropsychiatric manifestations, and immune dysregulation. Evidence from respiratory and oral microbiomes was more limited. Microbiome-targeted interventions, including probiotics, prebiotics, synbiotics, diet, and fecal microbiota transplantation (FMT), were mainly proposed or discussed, with limited direct interventional evidence. Current evidence suggests that microbiome alterations may be associated with Long COVID, but the available literature remains largely descriptive, observational, and hypothesis-generating. Further longitudinal and interventional studies are needed to clarify causality and determine whether microbiome-targeted strategies have therapeutic value.

Open Access PDF

Concepts Keywords
Cochrane Dysbiosis
Dysbiosis Gut microbiome
Frequently Long COVID
Library SARS-CoV-2
Probiotics

Semantics

Type Source Name
disease MESH dysbiosis
disease MESH long COVID
pathway REACTOME Metabolism
disease MESH included
disease MESH fatigue
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH Severe acute respiratory syndrome
disease MESH SARS CoV 2 infection
disease MESH chronic condition
disease MESH inflammation
disease MESH cognitive impairment
disease MESH mood disorders
drug DRUGBANK Factor IX Complex (Human)
disease MESH PCC
disease MESH infection
disease MESH Syndrome
drug DRUGBANK Methionine
disease MESH persistent infection
pathway KEGG Tryptophan metabolism
disease MESH obesity
disease MESH Chronic Cough
drug DRUGBANK Isoxaflutole
disease MESH cognitive symptoms
drug DRUGBANK Serotonin
disease MESH IBS
drug DRUGBANK Topiramate
disease MESH mitochondrial dysfunction
disease MESH Myalgic Encephalomyelitis
disease MESH Encephalopathy
disease MESH Neuroinflammation
drug DRUGBANK Guanosine
disease MESH PAIS
drug DRUGBANK Somatotropin
pathway REACTOME Immune System
disease MESH Viral Infections
disease MESH Neurodegenerative Disorders
pathway REACTOME Neurodegenerative Diseases
disease MESH relapse
disease MESH periodontal disease
drug DRUGBANK L-Tryptophan
disease MESH dyspnea
drug DRUGBANK Butyric Acid
disease MESH strains
drug DRUGBANK Phenethylamine
pathway KEGG Tight junction
disease MESH endotoxemia
disease MESH Neurological Manifestations
drug DRUGBANK Hydrocortisone
disease MESH inflammatory bowel disease
pathway KEGG Inflammatory bowel disease
disease MESH metabolic syndrome
pathway REACTOME Fatty acids
drug DRUGBANK Inulin
disease MESH GPA
disease MESH infectious diseases
disease MESH Dis
drug DRUGBANK Nelumbo nucifera flower
disease MESH neglected disease
disease MESH Autoimmune Diseases
disease MESH Allergy
disease MESH diarrhea
disease MESH irritable bowel syndrome
disease MESH Neurological Disorders

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *